MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$10.267M
Net Income
-$24.853M
Net Profit Margin
-242.07%
EPS
-$0.35
Unit: Million (M) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
10.267
3.733
-20*
10
Research and development
30.994
26.813
22*
34.629
General and administrative
10.963
11.133
11*
10.622
Total operating expenses
41.957
37.946
33*
45.251
Loss from operations
-31.69
-34.213
-53*
-35.251
Interest income
9.718
9.852
11
10.938
Total other income
9.718
9.852
11*
10.938
Net loss
-21.972
-24.361
-42*
-24.313
Unrealized loss on available-for-sale securities, net
-2.881
-3.74
-1*
0.815
Comprehensive loss
-24.853
-28.101
-43
-23.498
Basic EPS
-0.35
-0.39
-0.698
-0.39
Diluted EPS
-0.35
-0.39
-0.698
-0.39
Basic Average Shares
62,937,295
62,665,717
62,085,591
62,023,685
Diluted Average Shares
62,937,295
62,665,717
62,085,591
62,023,685
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$24.853M
Interest income
$9.718M
Net loss
-$21.972M
Unrealized loss on
available-for-sale securities, net
-$2.881M
Total other income
$9.718M
Loss from operations
-$31.69M
Collaboration revenue
$10.267M
Total operating
expenses
$41.957M
Research and development
$30.994M
General and
administrative
$10.963M
Buy us a coffee
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)